📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

📊 Sector Averages

About

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Key Ratios Snapshot

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

⭐ Superinvestors Holding NKTR

View All Superinvestors →

Manager	Shares	Value	% of Fund	Period
Jim Simons Renaissance Technologies LLC	41.8K	$3.0M	0.00%	Mar 2026
Steve Cohen Point72 Asset Management	13.4K	$962K	0.00%	Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 4 quarters analysed

Q2 2025

Confident Specific

Management used words like 'transformative', 'highly compelling', and 'establish REZPEG as a potential first-in-class' regarding atopic dermatitis data. They repeatedly emphasized differentiation from competitors and concrete timelines for Phase 3 readiness (first half 2026) and upcoming data catalysts.

Q3 2025

Confident Specific

Management uses strong language like 'compelling results', 'powerful translation', 'clearly support continued development', and 'very excited' to describe REZPEG data and upcoming catalysts. They emphasize differentiation and robust clinical data without defensive hedging.

Q4 2025

Confident Specific

Management used phrases like 'pivotal year', 'significant progress', 'first positive results', and provided specific data points (1,000 patients treated, 381 patient years exposure, $245.8M cash, $476M raised) indicating confidence in the path forward.

Q1 2026 latest

Confident Specific

Management repeatedly uses confident language such as 'exceptionally proud', 'compelling first-in-class biologic candidate', and 'very strong financial position', while providing specific numbers on trial design, timelines, and cash runway.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis for Nektar appears stronger after this call. Management delivered clear, specific timelines for phase III programs in atopic dermatitis and alopecia areata, supported by encouraging data on deepening efficacy and durability. The company's cash position of over $1 billion provides a long runway into late 2028, de-risking execution through key data readouts. The differentiation of REZPEG as a Treg mechanism with potential remittive properties and less frequent dosing is repeatedly emphasized. However, investors should watch for enrollment updates, the off-treatment durability data in Q1 2027, and the outcome of the end-of-phase II meeting with FDA for alopecia areata. The lack of specifics on the next new indication and regulatory feedback on moderate AA are near-term uncertainties. Overall, the call reinforces a bullish outlook contingent on successful phase III execution.

AI-generated concall tone analysis · Updated 2026-06-09 · Not investment advice

🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →

📊 MIXED Nektar advances REZPEG in AD and AA with over $1B cash.

Revenue & Profitability

Q1 2026 non-cash royalty revenue was $10.9M; full-year 2026 revenue is expected to total $40-45M. Net loss for Q1 was $44.9M. R&D expense was $35.7M (full-year guidance $200-250M), G&A expense was $13.4M (full-year guidance $60-65M). Non-cash interest expense was $7.9M in Q1, expected $30-35M for the year. Cash and investments at Q1 end were $731.6M; after an April financing totaling ~$350M net, the company now has over $1B in cash.

Outlook

Management highlighted significant unmet need: in the U.S., 15M people have moderate-to-severe AD but <10% receive biologics, and roughly half of patients on existing agents fail or lose response. In alopecia areata, 6.7M U.S. patients exist, the vast majority untreated, and dermatologists are reluctant to prescribe JAK inhibitors due to box warnings. The combined global markets for AD and AA are expected to reach nearly $40B over the next five years. Management draws a parallel to the psoriasis market, where new mechanisms expanded the treated patient population 10-fold over 15 years.

Growth Drivers

Key growth drivers are the advancement of REZPEG into phase III in atopic dermatitis (ZENITH-AD program starting July 2026) and alopecia areata (phase III start first part of 2027). Additional catalysts include off-treatment data in AD (Q1 2027) and AA (Q4 2026), initial data from the TrialNet type 1 diabetes study (2027), and a proof-of-concept study in a new indication (H2 2026, data 2027). Geographic expansion includes adding APAC sites in the phase III AD program.

Balance Sheet & CapEx

Not discussed in this earnings call.

Margins

No explicit margin guidance provided. The company is in a development stage with net losses ($44.9M net loss in Q1 2026). R&D and G&A expense guidance for 2026 is $200-250M and $60-65M respectively, with R&D increasing as phase III programs initiate.

Key Risks

Risks discussed include regulatory uncertainty (e.g., FDA acceptance of a single phase III trial for AA), potential high placebo effect in moderate AA patients, and the need to align on safety database requirements. Other risks are typical for development-stage biopharma: clinical trial execution, competition, and reliance on forward-looking statements as noted in the disclaimer.

Generated by AI · Q1 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q1 2026 Q1 2026 2026-05-07

REZPEG advanced with strong phase IIb data in atopic dermatitis and alopecia areata, supporting phase III trials and a BLA submission by 2029. Over $1 billion in cash ensures funding through key milestones, with a robust pipeline and favorable market outlook.

Q4 2025 Q4 2025 2026-03-12

Positive phase 2 results for REZPEG in atopic dermatitis and alopecia areata support advancement to phase 3, backed by a strong cash position and FDA alignment. 2025 ended with $245.8M cash, and $476M was raised in 2026 to fund late-stage trials.

Q3 2025 Q3 2025 2025-11-06

REZPEG advanced toward phase III in atopic dermatitis and phase IIb data in alopecia areata is expected in December, supported by strong efficacy, safety, and a robust cash position extending into 2027. The company raised significant capital and highlighted REZPEG's differentiation in autoimmune dermatology.

Q2 2025 Q2 2025 2025-08-07

Q2 2025 saw strong progress with REZPEG, including positive phase IIb data in atopic dermatitis and FDA Fast Track designations. Financially, the company ended the quarter with $175.9M in cash, completed major equity financings, and extended its cash runway into 2027.

Q1 2025 Q1 2025 2025-05-08

Immunology pipeline advanced with REZPEG in phase 2b studies for atopic dermatitis and alopecia areata, with key data readouts expected in June and December. Strong cash position ($220.7M), no debt, and guidance reaffirmed; collaboration likely needed for phase 3 REZPEG.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.